A Fixed-Dose Combination Of Gemigliptin And Rosuvastatin Exhibits Similar Pharmacokinetics, Pharmacodynamics, And Safety Compared To That Of A Loose Combination In Healthy Subjects

Overview

Journal Drug Des Devel Ther

Specialty Pharmacology

Date 2020 Feb 4

PMID 32009778

Citations 2

Authors

Eunwoo Kim

Kyoung Ryun Park

In-Jin Jang

Kyung-Sang Yu

Seunghwan Lee

Affiliations

Soon will be listed here.

Abstract

Purpose: Fixed-dose combination (FDC) of gemigliptin and rosuvastatin may improve medication compliance of patients with comorbid type 2 diabetes and dyslipidemia. Pharmacokinetics (PK), pharmacodynamics (PD), and safety of gemigliptin/rosuvastatin 50/20 mg FDC was compared with a loose combination of individual tablets in healthy subjects.

Patients And Methods: A randomized, open-label, single-dose, two-period, two-sequence, two-treatment crossover study was conducted. Subjects received FDC or a loose combination of gemigliptin (50 mg) and rosuvastatin (20 mg) during each period, with a 14-day washout. Serial blood samples were collected up to 72 hrs after dosing to measure plasma concentrations of gemigliptin, its active metabolite LC15-0636, and rosuvastatin for PK assessment, and DPP-4 activity for PD assessment. PK and PD parameters were calculated using a non-compartmental method. Safety profiles were evaluated throughout the study.

Results: Thirty-seven subjects completed the study. The concentration-time profiles of gemigliptin, LC15-0636, and rosuvastatin were similar between FDC and loose combination, respectively. For each of the three compounds, the geometric mean ratios (90% confidence interval) of FDC to loose combination for C and AUC fell within the bioequivalence range of 0.8-1.25. Inhibition of DPP-4 activity-time profiles after administration of FDC and loose combination was overlapping, and I and AUEC were similar. Both FDC and the loose combination were well tolerated.

Conclusion: PK, PD, and safety profiles of gemigliptin, its metabolite, and rosuvastatin were similar between FDC and loose combination. The FDC of gemigliptin (50 mg) and rosuvastatin (20 mg) can be used as an alternative to a loose combination, which is expected to improve patient compliance.

Citing Articles

In-lab synthesized turn-off fluorescence sensor for estimation of Gemigliptin and Rosuvastatin polypill appraised by Spider diagram, AGREE and whiteness metrics.

Mohyeldin S, Talaat W, Kamal M, Daabees H, El-Tahawy M, Keshk R Sci Rep. 2024; 14(1):2927.

PMID: 38316908 PMC: 10844310. DOI: 10.1038/s41598-024-53203-z.

Pharmacokinetic and Pharmacodynamic Comparison of Two Formulations of a Fixed-Dose Combination of Gemigliptin/Rosuvastatin 50/20 mg: A Randomized, Open-Label, Single-Dose, Two-Way Crossover Study.

Yang E, Yoo H, Jang I, Yu K, Lee S Drug Des Devel Ther. 2021; 15:651-658.

PMID: 33628012 PMC: 7898221. DOI: 10.2147/DDDT.S288986.

References

Kim S, Yoo J, Lee W, Park C . Gemigliptin: An Update of Its Clinical Use in the Management of Type 2 Diabetes Mellitus. Diabetes Metab J. 2016; 40(5):339-353. PMC: 5069390. DOI: 10.4093/dmj.2016.40.5.339. View

Choi H, Lim H, Kim Y, Jeon H, Kim M, Lee S . Evaluation of the pharmacokinetics of the DPP-4 inhibitor gemigliptin when coadministered with rosuvastatin or irbesartan to healthy subjects. Curr Med Res Opin. 2014; 31(2):229-41. DOI: 10.1185/03007995.2014.980886. View

Yang S, Min K, Gupta S, Park J, Shivane V, Pitale S . A multicentre, multinational, randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of gemigliptin (LC15-0444) in patients with type 2 diabetes. Diabetes Obes Metab. 2012; 15(5):410-6. DOI: 10.1111/dom.12042. View

Olsson A, McTaggart F, Raza A . Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor. Cardiovasc Drug Rev. 2002; 20(4):303-28. DOI: 10.1111/j.1527-3466.2002.tb00099.x. View

Iglay K, Hannachi H, Joseph Howie P, Xu J, Li X, Engel S . Prevalence and co-prevalence of comorbidities among patients with type 2 diabetes mellitus. Curr Med Res Opin. 2016; 32(7):1243-52. DOI: 10.1185/03007995.2016.1168291. View

Mooradian A . Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab. 2009; 5(3):150-9. DOI: 10.1038/ncpendmet1066. View

Ullah F, Afridi A, Rahim F, ur Rahman S, Ashfaq M . EFFICACY OF 5 MG AND 10 MG ROSUVASTATIN IN TYPE-2 DIABETES MELLITUS WITH HYPERCHOLESTEROALEMIA. J Ayub Med Coll Abbottabad. 2016; 27(3):564-8. View

Khavandi M, Duarte F, Ginsberg H, Reyes-Soffer G . Treatment of Dyslipidemias to Prevent Cardiovascular Disease in Patients with Type 2 Diabetes. Curr Cardiol Rep. 2017; 19(1):7. PMC: 5503120. DOI: 10.1007/s11886-017-0818-1. View

Olsson A, Pears J, McKellar J, Mizan J, Raza A . Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. Am J Cardiol. 2001; 88(5):504-8. DOI: 10.1016/s0002-9149(01)01727-1. View

10.

Lee E, Ryan S, Birmingham B, Zalikowski J, March R, Ambrose H . Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther. 2005; 78(4):330-41. DOI: 10.1016/j.clpt.2005.06.013. View

11.

Lim K, Kim J, Choi Y, Shin K, Kim K, Hong J . Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study. Clin Ther. 2008; 30(10):1817-30. DOI: 10.1016/j.clinthera.2008.10.013. View

12.

Kim S, Lee S, Yim H . Gemigliptin, a novel dipeptidyl peptidase 4 inhibitor: first new anti-diabetic drug in the history of Korean pharmaceutical industry. Arch Pharm Res. 2013; 36(10):1185-8. DOI: 10.1007/s12272-013-0171-x. View

13.

Garber A, Abrahamson M, Barzilay J, Blonde L, Bloomgarden Z, Bush M . CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2018 EXECUTIVE SUMMARY. Endocr Pract. 2018; 24(1):91-120. DOI: 10.4158/CS-2017-0153. View

14.

Wolffenbuttel B, Franken A, Vincent H . Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes -- CORALL study. J Intern Med. 2005; 257(6):531-9. DOI: 10.1111/j.1365-2796.2005.01499.x. View

15.

Tuomilehto J, Leiter L, Kallend D . A review of the efficacy of rosuvastatin in patients with type 2 diabetes. Int J Clin Pract Suppl. 2005; (143):30-40. DOI: 10.1111/j.1368-504x.2004.00390.x. View

16.

Ahren B . DPP-4 inhibitors. Best Pract Res Clin Endocrinol Metab. 2007; 21(4):517-33. DOI: 10.1016/j.beem.2007.07.005. View

17.

Kim N, Patrick L, Mair S, Stevens L, Ford G, Birks V . Absorption, metabolism and excretion of [14C]gemigliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans. Xenobiotica. 2013; 44(6):522-30. DOI: 10.3109/00498254.2013.865856. View

18.

Tzeng T, Schneck D, Birmingham B, Mitchell P, Zhang H, Martin P . Population pharmacokinetics of rosuvastatin: implications of renal impairment, race, and dyslipidaemia. Curr Med Res Opin. 2008; 24(9):2575-85. DOI: 10.1185/03007990802312807. View

19.

Shin D, Cho Y, Lee S, Lim K, Kim J, Ahn J . Pharmacokinetic and pharmacodynamic interaction between gemigliptin and metformin in healthy subjects. Clin Drug Investig. 2014; 34(6):383-93. DOI: 10.1007/s40261-014-0184-3. View

20.

Noh Y, Lim H, Jin S, Kim M, Kim Y, Sung H . Effects of ketoconazole and rifampicin on the pharmacokinetics of gemigliptin, a dipeptidyl peptidase-IV inhibitor: a crossover drug-drug interaction study in healthy male Korean volunteers. Clin Ther. 2012; 34(5):1182-94. DOI: 10.1016/j.clinthera.2012.04.001. View